97 related articles for article (PubMed ID: 24103300)
1. Synthesis and immunological activity of an oligosaccharide-conjugate as a vaccine candidate against Group A Streptococcus.
Auzanneau FI; Borrelli S; Pinto BM
Bioorg Med Chem Lett; 2013 Nov; 23(22):6038-42. PubMed ID: 24103300
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and immunological characterization of modified hyaluronic acid hexasaccharide conjugates.
Gu G; Adabala PJ; Szczepina MG; Borrelli S; Pinto BM
J Org Chem; 2013 Aug; 78(16):8004-19. PubMed ID: 23848545
[TBL] [Abstract][Full Text] [Related]
3. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
[TBL] [Abstract][Full Text] [Related]
4. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
5. Semisynthetic Glycoconjugate Vaccines To Elicit T Cell-Mediated Immune Responses and Protection against
Feng S; Xiong C; Wang S; Guo Z; Gu G
ACS Infect Dis; 2019 Aug; 5(8):1423-1432. PubMed ID: 31126171
[No Abstract] [Full Text] [Related]
6. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
[TBL] [Abstract][Full Text] [Related]
7. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate.
Kabanova A; Margarit I; Berti F; Romano MR; Grandi G; Bensi G; Chiarot E; Proietti D; Swennen E; Cappelletti E; Fontani P; Casini D; Adamo R; Pinto V; Skibinski D; Capo S; Buffi G; Gallotta M; Christ WJ; Campbell AS; Pena J; Seeberger PH; Rappuoli R; Costantino P
Vaccine; 2010 Dec; 29(1):104-14. PubMed ID: 20870056
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.
Konadu E; Shiloach J; Bryla DA; Robbins JB; Szu SC
Infect Immun; 1996 Jul; 64(7):2709-15. PubMed ID: 8698499
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
13. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection.
Sabharwal H; Michon F; Nelson D; Dong W; Fuchs K; Manjarrez RC; Sarkar A; Uitz C; Viteri-Jackson A; Suarez RS; Blake M; Zabriskie JB
J Infect Dis; 2006 Jan; 193(1):129-35. PubMed ID: 16323141
[TBL] [Abstract][Full Text] [Related]
14. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
16. Designer vaccines to prevent infections due to group B Streptococcus.
Kasper DL
Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
[TBL] [Abstract][Full Text] [Related]
17. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
[TBL] [Abstract][Full Text] [Related]
18. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
Paoletti LC; Pinel J; Kennedy RC; Kasper DL
J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
Paoletti LC; Pinel J; Rodewald AK; Kasper DL
J Infect Dis; 1997 May; 175(5):1237-9. PubMed ID: 9129094
[TBL] [Abstract][Full Text] [Related]
20. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
